Pharsight

Drug Patents owned by Chemocentryx

1. Drug name - TAVNEOS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8906938 CHEMOCENTRYX C5aR antagonists
Dec, 2029

(7 years from now)

US8445515 CHEMOCENTRYX C5aR antagonists
Feb, 2031

(8 years from now)

CN102264227B CHEMOCENTRYX C5A Antagonist
Dec, 2029

(7 years from now)

CN102264227A CHEMOCENTRYX C5A Antagonist
Dec, 2029

(7 years from now)

CN103068385B CHEMOCENTRYX C5A Antagonist
Jun, 2031

(8 years from now)

CN103068385A CHEMOCENTRYX C5A Antagonist
Jun, 2031

(8 years from now)

IN298319B CHEMOCENTRYX C5Ar Antagonists
Dec, 2029

(7 years from now)

IN201103071P2 CHEMOCENTRYX C5Ar Antagonists
Dec, 2029

(7 years from now)

EP2381778B1 CHEMOCENTRYX C5Ar Antagonists
Dec, 2029

(7 years from now)

EP2381778A1 CHEMOCENTRYX C5Ar Antagonists
Dec, 2029

(7 years from now)

EP3508477A1 CHEMOCENTRYX C5Ar Antagonists
Dec, 2029

(7 years from now)

EP2381778A4 CHEMOCENTRYX C5Ar Antagonists
Dec, 2029

(7 years from now)

EP3508477B1 CHEMOCENTRYX C5Ar Antagonists
Dec, 2029

(7 years from now)

EP3078658B1 CHEMOCENTRYX C5Ar Antagonists
Dec, 2029

(7 years from now)

EP3078658A1 CHEMOCENTRYX C5Ar Antagonists
Dec, 2029

(7 years from now)

EP2585064A4 CHEMOCENTRYX C5Ar Antagonists
Jun, 2031

(8 years from now)

EP2585064A1 CHEMOCENTRYX C5Ar Antagonists
Jun, 2031

(8 years from now)

EP2585064B1 CHEMOCENTRYX C5Ar Antagonists
Jun, 2031

(8 years from now)

Drugs and Companies using AVACOPAN ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
10MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.